The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April. 

Two new PD-(L)1 x VEGF projects have entered the clinic.

The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.

First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.